IBM Cloud Pak System 2.3.3.7/2.3.3.7 iFix1/2.3.5.0 cross site scripting
| CVSS Meta Temp Score | Current Exploit Price (≈) | CTI Interest Score |
|---|---|---|
| 4.7 | $0-$5k | 0.00 |
Summary
A vulnerability marked as problematic has been reported in IBM Cloud Pak System 2.3.3.7/2.3.3.7 iFix1/2.3.5.0. This affects an unknown function. Performing a manipulation results in cross site scripting. This vulnerability is reported as CVE-2023-38007. The attack is possible to be carried out remotely. No exploit exists. It is suggested to upgrade the affected component.
Details
A vulnerability, which was classified as problematic, was found in IBM Cloud Pak System 2.3.3.7/2.3.3.7 iFix1/2.3.5.0. This affects an unknown code. The manipulation with an unknown input leads to a cross site scripting vulnerability. CWE is classifying the issue as CWE-80. The product receives input from an upstream component, but it does not neutralize or incorrectly neutralizes special characters such as "<", ">", and "&" that could be interpreted as web-scripting elements when they are sent to a downstream component that processes web pages. This is going to have an impact on integrity. The summary by CVE is:
IBM Cloud Pak System 2.3.5.0, 2.3.3.7, 2.3.3.7 iFix1 on Power and 2.3.3.6, 2.3.3.6 iFix1, 2.3.3.6 iFix2, 2.3.4.0, 2.3.4.1 on Intel operating systems is vulnerable to HTML injection. A remote attacker could inject malicious HTML code, which when viewed, would be executed in the victim's Web browser within the security context of the hosting site.
The advisory is shared at ibm.com. This vulnerability is uniquely identified as CVE-2023-38007 since 07/11/2023. The exploitability is told to be easy. It is possible to initiate the attack remotely. It demands that the victim is doing some kind of user interaction. Neither technical details nor an exploit are publicly available. MITRE ATT&CK project uses the attack technique T1059.007 for this issue.
Upgrading eliminates this vulnerability.
The vulnerability is also documented in the vulnerability database at EUVD (EUVD-2023-41834). If you want to get the best quality for vulnerability data then you always have to consider VulDB.
Product
Type
Vendor
Name
Version
License
Website
- Vendor: https://www.ibm.com/
CPE 2.3
CPE 2.2
CVSSv4
VulDB Vector: 🔒VulDB Reliability: 🔍
CVSSv3
VulDB Meta Base Score: 4.8VulDB Meta Temp Score: 4.7
VulDB Base Score: 3.5
VulDB Temp Score: 3.4
VulDB Vector: 🔒
VulDB Reliability: 🔍
NVD Base Score: 5.4
NVD Vector: 🔒
CNA Base Score: 5.4
CNA Vector (ibm): 🔒
CVSSv2
| AV | AC | Au | C | I | A |
|---|---|---|---|---|---|
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| Vector | Complexity | Authentication | Confidentiality | Integrity | Availability |
|---|---|---|---|---|---|
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
VulDB Base Score: 🔒
VulDB Temp Score: 🔒
VulDB Reliability: 🔍
Exploiting
Class: Cross site scriptingCWE: CWE-80 / CWE-74 / CWE-707
CAPEC: 🔒
ATT&CK: 🔒
Physical: No
Local: No
Remote: Yes
Availability: 🔒
Status: Not defined
EPSS Score: 🔒
EPSS Percentile: 🔒
Price Prediction: 🔍
Current Price Estimation: 🔒
| 0-Day | Unlock | Unlock | Unlock | Unlock |
|---|---|---|---|---|
| Today | Unlock | Unlock | Unlock | Unlock |
Threat Intelligence
Interest: 🔍Active Actors: 🔍
Active APT Groups: 🔍
Countermeasures
Recommended: UpgradeStatus: 🔍
0-Day Time: 🔒
Timeline
07/11/2023 CVE reserved06/27/2025 Advisory disclosed
06/27/2025 VulDB entry created
08/14/2025 VulDB entry last update
Sources
Vendor: ibm.comAdvisory: ibm.com
Status: Confirmed
CVE: CVE-2023-38007 (🔒)
GCVE (CVE): GCVE-0-2023-38007
GCVE (VulDB): GCVE-100-314157
EUVD: 🔒
Entry
Created: 06/27/2025 17:21Updated: 08/14/2025 06:17
Changes: 06/27/2025 17:21 (64), 06/27/2025 18:36 (1), 08/14/2025 06:17 (12)
Complete: 🔍
Cache ID: 216::103
If you want to get the best quality for vulnerability data then you always have to consider VulDB.
No comments yet. Languages: en.
Please log in to comment.